Thank you for subscribing to our blog.
We’ll hit your inbox next week with our latest post.

Latest Insights and Updates Delivered to your Inbox!

Subscribe now for exciting weekly industry news!

How Navitas Life Sciences’ Advisory Services Power Transformation Across the Drug Development Lifecycle
The success of drug development, commercialization & lifecycle management hinges on the ability to anticipate challenges, accelerate innovation, and adopt intelligent transformation strategies. Whether complying with regulatory changes, modernizing data systems, or optimizing clinical operations, life sciences companies need a strategic partner...
World Asthma Day: Advancing Respiratory Clinical Trials
World Asthma Day is a timely reminder of the growing global burden of asthma and the urgent need for new solutions. Asthma is a major chronic respiratory disease affecting people of all ages. It is the most common chronic disease among children are essential to bring those innovations to patients quickly and safely. The Growing Burden of Asthma and...
How We Build Custom FSP Solutions to Rescue Trials
When studies stall or derail, sponsors need a clinical trial rescue strategy that’s fast, cost- & time-efficient, and experienced with highly qualified data experts. As a leading Biometrics CRO, Navitas Life Sciences has designed flexible, scalable Functional Service Provider (FSP) models tailored to meet diverse sponsor needs and budget...
Navitas Life Sciences Empowers Emerging Biopharma to Accelerate Innovation
Built for Biotech. Start Smart. Scale Fast. Breakthrough science begins with bold ambition and realizing its potential takes the right partner. As an experienced Biotech CRO, Navitas Life Sciences recognizes the unique challenges that emerging biopharma and biotech innovators face: limited resources, accelerated timelines, and the critical need to ...
Consumer Healthcare Product Safety: What now, Where Next?
The inaugural Consumer Healthcare (CHC) Safety Roundtable, hosted by Navitas pvnetworks and led by industry leaders Dr. Latika Sharma, MBBS, MD, Ben Parsons, and Dr. Sara Hall, PhD, served as a pivotal gathering for discussing the evolving landscape of consumer healthcare product safety. In this exclusive event, distinguished industry experts, Viny...
Parkinson’s Foundation’s PD GENERation Study: Strategic Partnership with Navitas Life Sciences
As the world observes World Parkinson’s Day on April 11th, a day dedicated to raising awareness about Parkinson’s disease and honouring Dr. James Parkinson, who first described the condition in 1817, the spotlight turns to groundbreaking initiatives that harness genetic research to transform patient care. One such initiative, PD GENEr...
World Health Day 2025: Maternal and Newborn Health
On April 7, 2025, we join the World Health Organisation, under the banner of Healthy beginnings, hopeful futures. The World Health Day 2025 campaign urges stakeholders to take decisive action against preventable maternal and newborn deaths. Over 300,000 women lose their lives annually due to pregnancy or childbirth, and 4 million newborns die or ar...
Reimagining Medical Writing – Data, Digital, and Automation
The pharmaceutical industry is experiencing a paradigm shift in medical writing, driven by artificial intelligence (AI), structured content authoring, and automation. Navitas Life Sciences’ 3rd Medical Writing Roundtable, hosted by Dr Latika Sharma and Dr. Sara Giadrossi, brought together industry leaders from 10+ global pharmaceutical compa...
Driving Digital Innovation in Regulatory Submissions with Navitas Life Sciences
The pharmaceutical industry is undergoing a significant transformation driven by digital innovation and artificial intelligence (AI). It has become increasingly beneficial to leverage AI powered tools and cloud based regulatory solutions to streamline regulatory submissions. These advancements enhance efficiency, improve data exchange, and ensure c...
How Navitas Delivers Best-in-Class Bioavailability & Bioequivalence Study Services
The global generics market is on an accelerated growth path, with the U.S. leading the way, projected to surpass USD 508.37 billion by 2034 at a CAGR of 12.00%. This momentum is driven by rising healthcare costs, expiring patents, and increasing regulatory support for generic drug approvals. However, growth brings complexity. Regulatory scrutiny is...

Solutions

Advisory Services

Clinical Development

Post Marketing

Therapeutics

Core Therapeutics

Interdisciplinary Therapeutics

Niche Therapeutics

Sectors

Governance

About Us